Introduction Tolebrutinib is a next-generation Bruton’s tyrosine kinase inhibitor designed to target inflammatory pathways that remain insufficiently controlled by current multiple sclerosis therapies (1). Through covalent BTK binding, it delivers durable and selective inhibition across peripheral immune cells and CNS-resident microglia (1). Its co
Male Complaining of Bilateral Knee Pain and Gait Disturbance
840 Reached5 Comments1 Likes
Young Girl Presented with Irritability and Abnormal Behavior
2254 Reached10 Comments4 Likes
Management of Infantile Myoclonic Seizures
1169 Reached3 Comments3 Likes
Unconscious Male in ED following Loss of Motorcycle Control
828 Reached2 Comments2 Likes
Headache with Clinically Non-functioning Pituitary Adenoma
818 Reached1 Comments4 Likes